Press Release

AB-Therapeutics Announces the Launch of its New Web Site www.ab-therapeutics.com

June 15, 2011

AB-Therapeutics SL, a clinical-stage pharmaceutical biotech company in early 2012, today announced the launch of its new Web site: www.ab-therapeutics.com. The new Web site is designed as a comprehensive resource for investors, prospective corporate partners and the life science community to learn more about AB-Therapeutics’s business model, pipeline, partnerships and innovative technology.

“Our significant developments in the past year, including taking our first product into regulatory preclinical development, has opened new prospects for our company as we expect to initiate First in Man clinical trial as early as 1Q2012”. “This new site provides visitors an architecture that facilitates quick and efficient access to the information they need”, said Carles Domènech, PhD, Chief Executive Officer of AB-Therapeutics.

ABOUT AB-THERAPEUTICS

AB-Therapeutics is a drug discovery and development company headquartered in Barcelona, Catalonia, Spain, with planned US facilities in Boston. The company was cofounded in late 2009 by AB Biotics, SA, a company publicly traded at the Spanish alternative stock market (MAB), Carles Domenech (CEO) and Jordi Espadaler (VP Discovery Research).
AB-Therapeutics develops safer human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. It has a product ABT0812 in regulatory preclinical development, with Phase I clinical trials (first in man) starting early 2012. A second drug candidate ABT1014 will start preclinical development in 4Q2011.
Contact:
 
Media relations:
Nuria Peláez
Tel. +34 902 903 844
media.relations@ab-therapeutics.com
www.ab-therapeutics.com
 
 
Investors:
Carles Domènech, PhD
Tel. +34 935 868 977
contact@ab-therapeutics.com
www.ab-therapeutics.com

LATEST NEWS

09.09.2024

Press Release

IBRILATAZAR (ABTL0812) from AbilityPharma increases chemotherapy effectiveness by 40% in patients with endometrial cancer + info
30.07.2024

Press Release

AbilityPharma receives WHO approval for its ABTL0812 anticancer drug to be named IBRILATAZAR + info
16.07.2024

Press Release

AGC Pharma Chemicals and AbilityPharma work together to produce innovative treatment for pancreatic cancer + info
11.03.2024

Press Release

AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic Cancer + info
02.06.2023

Press Release

Ability Pharmaceuticals announces the presentation of the phase 2a results of ABTL0812 as first-line therapy in patients with lung cancer at the ASCO 2023 Annual Meeting in Chicago + info
14.12.2022

Press Release

AbilityPharma Achieves the 30% of the Estimated Recruitment for their Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as a First-Line Therapy Treatment in Advanced Pancreatic Cancer + info
21.11.2022

Press Release

AbilityPharma Obtains 1,5M € of Non-Dilutive Funding from Next Generation EU Funds to Further Study the Anticancer Immunomodulatory Effects of ABTL0812 + info
10.11.2022

Press Release

AbilityPharma will attend LSX investical showcase in London to meet with key investors and venture capital firms + info
02.11.2022

Press Release

ABTL0812 shows potential against glioblastoma brain tumors + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG